ulbi20210723_8k.htm
false 0000875657 0000875657 2021-07-21 2021-07-21
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
July 21, 2021
Date of Report (Date of Earliest Event Reported)
 
 
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware
000-20852
16-1387013
(State of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
2000 Technology Parkway, Newark, New York 14513
(Address of principal executive offices) (Zip Code)
 
(315) 332-7100
(Registrant’s telephone number, including area code)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Common Stock, $0.10 par value per share
ULBI
NASDAQ
(Title of each class)
(Trading Symbol)
(Name of each exchange on which registered)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
Item 5.07         Submission of Matters to a Vote of Security Holders.
 
On July 21, 2021, Ultralife Corporation (“the Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on May 25, 2021 (the “Record Date”) were entitled to vote at the Annual Meeting. As of the Record Date, there were 16,040,054 shares of common stock outstanding and entitled to vote, of which 13,897,805 (86.6%) were present in person or by proxy, representing a quorum. The results of stockholder voting on the proposals presented were as follows:
 
1. The Company’s stockholders elected five Directors, all of whom constitute the Company’s entire Board of Directors, to serve for a term of one year and until their successors are duly elected and qualified. The number of shares that (i) voted for the election of each Director, (ii) withheld authority to vote for each Director, and (iii) were broker non-votes, are set forth in the table below.
 
Director
For
Withheld
Broker Non-Votes
       
Michael D. Popielec
11,527,351
137,360
2,233,094
Thomas L. Saeli
10,893,438
771,273
2,223,094
Robert W. Shaw II
10,892,439
772,272
2,233,094
Ranjit C. Singh
9,654,030
2,010,681
2,233,094
Bradford T. Whitmore
10,873,177
791,534
2,233,094
 
 
2. The Company’s stockholders approved an amendment to the Company’s 2014 Long-Term Incentive Plan increasing the number of shares authorized under the plan. The number of shares that (i) voted for the resolution, (ii) voted against the resolution, (iii) abstained from the vote, and (iv) were broker non-votes, are set forth in the table below.
 
For
Against
Abstain
Broker Non-Votes
       
11,157,391 463,629 43,691 2,233,094
 
 
3. The Company’s stockholders ratified the selection of the Company’s independent registered public accounting firm as Freed Maxick CPAs, P.C. for 2021. The number of shares that (i) voted for the ratification of the accounting firm, (ii) voted against the ratification, and (iii) abstained from the vote are set forth in the table below.
 
For
Against
Abstain
     
13,868,292
12,368
17,145
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: July 23, 2021
 
ULTRALIFE CORPORATION
     
     
 
By:
/s/ Philip A. Fain
   
Philip A. Fain
   
Chief Financial Officer and Treasurer